今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

盒马自有品牌强势登陆美国市场，开启全球化新篇章

上海/北京/纽约 - 2024年6月6日，中国领先的鲜食零售商盒马鲜生宣布，旗下自有品牌商品已正式入驻美国最大的华人连锁超市大华超市和北美最大的华人购物网站亚米网站。这标志着盒马自有品牌首次大规模走出中国，迈出了全球化发展的重要一步。

此次进驻美国的商品，主要为休闲零食和粮油速食品类，包括料理酱汁类（麻酱、椒麻汁、炖煮包等）、零食类（瓜子、山楂条、苏打饼干、海盐太妃糖等）、米面类（刀削面、龙口粉丝等）。这些商品均经过严格的品质筛选，并结合美国消费者的口味习惯进行调整，在保持中国特色风味的同时，也更加符合当地市场需求。

盒马自有品牌自创立以来，始终坚持以高品质、高性价比、高颜值著称，深受中国消费者的喜爱。目前，盒马已拥有超过2000款自有品牌商品，涵盖鲜食、干货、调味品、日用品等多个品类。此次进驻美国，是盒马自有品牌全球化战略的重要一步，旨在将高品质的中国产品带给全球消费者。

盒马出海业务负责人演妮表示：“美国是全球华人分布最多的国家，因此成为了盒马出海的第一站。我们希望通过将盒马自有品牌引入美国，能够满足海外华人消费者的中国食品需求，同时也让更多美国消费者了解和喜爱中国美食文化。”

盒马的此次出海，也为中国零售企业的全球化发展树立了新的标杆。业内人士表示，盒马自有品牌的成功出海，不仅证明了中国产品在海外市场的竞争力，也为中国品牌走出去提供了宝贵经验。

未来，盒马还将继续拓展全球市场，计划进入澳大利亚、东南亚、日韩等国家和地区，将高品质的中国产品带给更多全球消费者。

以下是对新闻稿主要信息的扩充：

• 盒马自有品牌在美国的售价将略高于中国市场，以反映当地的进口关税和运营成本。
• 盒马计划未来在美国开设线下门店，为消费者提供更加便利的购物体验。
• 盒马还将与美国当地的餐饮企业合作，推出联名产品和服务。

以下是一些新的标题建议：

• 盒马自有品牌强势登陆美国，中国零售迈出全球化新步伐
• 盒马：将中国味道带向世界，自有品牌开启全球化征程
• 盒马出海美国，华人消费者终于可以买到家乡味道